Skip to main content
Top
Published in:

Open Access 01-12-2022 | Kidney Injury | Research

Biological variation in the serum and urine kidney injury markers of a healthy population measured within 24 hours

Authors: Li-Rui Kong, Fei Wei, Da-Hai He, Chao-Qiong Zhou, Hong-chuan Li, Feng Wu, Yu Luo, Jian-wei Luo, Qian-rong Xie, Hai Peng, Yan Zhang

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background and aims

To explore the biological variation (BV) of kidney injury markers in serum and urine of healthy subjects within 24 hours to assist with interpretation of future studies using these biomarkers in the context of known BV.

Materials and methods

Serum and urine samples were collected every 4 hours (0, 4, 8, 12, 16 and 20 hours) from 31 healthy subjects within 24 hours and serum creatinine (s-Crea), serum β2-microglobin (s-β2MG), serum cystatin C (s-CYSC), serum neutrophil gelatinase-associated lipoprotein (s-NGAL), urine creatinine (u-Crea), urine β2-microglobin (u-β2MG), urine cystatin C (u-CYSC), urine neutrophil gelatinase-associated lipoprotein (u-NGAL) were measured. Outlier and variance homogeneity analyses were performed, followed by CV-ANOVA analysis on trend-corrected data (if relevant), and analytical (CVA), within-subject (CVI), and between-subject (CVG) biological variation were calculated.

Results

The concentration of kidney injury markers in male was higher than that in female, except for u-CYSC and u-NGAL. There were no significant difference in serum and urine kidney injury markers concentration at different time points. Serum CVI was lower than urine CVI, serum CVG was higher than CVI, and urine CVG was lower than CVI. The individual index (II) of serum kidney injury markers was less than 0.6, while the II of urinary kidney injury markers was more than 1.0.

Conclusions

This study provides new short-term BV data for kidney injury markers in healthy subjects within 24 hours, which are of great significance in explaining other AKI / CKD studies.
Literature
11.
go back to reference Aarsand AK, F.-C. P., Webster C, Coskun A, Gonzales-Lao E, Diaz-Garzon J, Jonker N, Minchinela J, Simon M, Braga F, Perich C, Boned B, Roraas T, Marques-Garcia F, Carobene A, Aslan B, Barlett WA, Sandberg S. The EFLM Biological Variation Database. 2020. https://biologicalvariation.eu/. Aarsand AK, F.-C. P., Webster C, Coskun A, Gonzales-Lao E, Diaz-Garzon J, Jonker N, Minchinela J, Simon M, Braga F, Perich C, Boned B, Roraas T, Marques-Garcia F, Carobene A, Aslan B, Barlett WA, Sandberg S. The EFLM Biological Variation Database. 2020. https://​biologicalvariat​ion.​eu/​.
17.
go back to reference Shaphiro SS, Wilk MBJB. An analysis of variance test for normality (Complete Samples). Biometrika. 1965;52:591–611.CrossRef Shaphiro SS, Wilk MBJB. An analysis of variance test for normality (Complete Samples). Biometrika. 1965;52:591–611.CrossRef
18.
19.
go back to reference Snedecor GW, Cochran WG. Statistical Methods. 8th ed. 1989. Snedecor GW, Cochran WG. Statistical Methods. 8th ed. 1989.
22.
go back to reference Harris EK, B. J. in Statistical Bases of Reference Values in Laboratory Medicine Ch. Comparison of within-subject and among-subjects variance. N.Y: Marcel Dekker, Inc; 1995. p. 187–221. Harris EK, B. J. in Statistical Bases of Reference Values in Laboratory Medicine Ch. Comparison of within-subject and among-subjects variance. N.Y: Marcel Dekker, Inc; 1995. p. 187–221.
26.
go back to reference Dong XM, et al. Predictive value of plasma beta2-microglobulin on human body function and senescence. Eur Rev Med Pharmacol Sci. 2016;20:2350–6.PubMed Dong XM, et al. Predictive value of plasma beta2-microglobulin on human body function and senescence. Eur Rev Med Pharmacol Sci. 2016;20:2350–6.PubMed
30.
go back to reference Eckfeldt, J. H., Chambless, L. E. & Shen, Y. L. Short-term, within-person variability in clinical chemistry test results. Experience from the Atherosclerosis Risk in Communities Study. Arch Pathol Lab Med. 1994;118:496–500. Eckfeldt, J. H., Chambless, L. E. & Shen, Y. L. Short-term, within-person variability in clinical chemistry test results. Experience from the Atherosclerosis Risk in Communities Study. Arch Pathol Lab Med. 1994;118:496–500.
Metadata
Title
Biological variation in the serum and urine kidney injury markers of a healthy population measured within 24 hours
Authors
Li-Rui Kong
Fei Wei
Da-Hai He
Chao-Qiong Zhou
Hong-chuan Li
Feng Wu
Yu Luo
Jian-wei Luo
Qian-rong Xie
Hai Peng
Yan Zhang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02819-2

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare